Telix share price charges higher on FDA news

The Telix Pharmaceuticals Ltd (ASX:TLX) share price is charging higher following the release of a positive update this morning…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a strong performer on Thursday.

In morning trade the clinical-stage biopharmaceutical company's shares are up 3.5% to $1.50.

Why is the Telix Pharmaceuticals share price charging higher?

Investors have been buying Telix's shares on Thursday after the release of an update on its Zirconium Imaging in Renal Cancer Oncology (ZIRCON) study.

According to the release, the US Food and Drug Administration (FDA) has approved the recruitment of American patients for its ZIRCON study. The receipt of the Investigational New Drug (IND) notice of allowance will enable patient recruitment to commence in the United States in 30 days.

ZIRCON is an international Phase III study to evaluate the utility of TLX250-CDx (89Zr-girentuximab) for the imaging of clear cell renal cell cancer (ccRCC) using Positron Emission Tomography.

The study is aiming to recruit approximately 250 patients and is currently recruiting at 19 sites in Australia and Europe. The IND allowance in the United States will add up to six leading cancer centres in the United States.

Management expects the trial to complete its enrolment in the middle of 2020.

Telix's CEO, Dr. Christian Behrenbruch, believes that this development is a major milestone for the company.

He said: "This IND is a major milestone for the company in terms of moving ahead the ZIRCON study as well as engagement with US regulators for a late-stage trial. We are excited to be adding US patients to the study. We'd also like to thank our North American manufacturing and pharmacy partners – Isologic and Cardinal Health – for their support with this submission."

What is TLX250-CDx?

TLX250-CDx is an antibody-based imaging agent for use with Positron Emission Tomography.

It targets a cell surface antigen called Carbonic Anhydrase IX (CAIX). It is expressed on the vast majority of ccRCC, which is the most common form of kidney cancer.

CAIX is also highly expressed in many other cancers with poor prognosis, such as pancreatic, bladder, colorectal and lung cancers.

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »